Escrito por estudiantes que aprobaron Inmediatamente disponible después del pago Leer en línea o como PDF ¿Documento equivocado? Cámbialo gratis 4,6 TrustPilot
logo-home
Document preview thumbnail
Vista previa 4 fuera de 49 páginas
Examen

Wilkes University NSG 533 Exam 3 (pdf) | 2026/2027 | Advanced Pharmacology Q&A | Pharmacology

Document preview thumbnail
Vista previa 4 fuera de 49 páginas

This document helps you master Exam 3 of NSG 533 Advanced Pharmacology at Wilkes University via targeted Q&A with detailed rationales. It covers high-yield pharmacologic concepts for advanced practice, including cardiovascular pharmacology (heart failure with HFpEF vs. HFrEF, digoxin toxicity, nitrates, beta-blockers, diuretics), lipid management (atherosclerosis, dyslipidemia, LDL/HDL function), and renal considerations. You will also master pharmacotherapeutics for endocrine, gastrointestinal, and psychiatric conditions. The material is aligned with major evidence-based guidelines including ACC/AHA, ADA, GINA, GOLD, CDC, IDSA, and FDA standards. Engineered for retention and clinical judgment with NGN-style case studies, this test pack simplifies complex graduate-level pharmacology, saving preparation time and ensuring you secure an A on your NSG 533 Exam 3 assessment.

Vista previa del contenido

Wilkes University NSG 533 Exam 3 (pdf) | 2026/2027 | Advanced
Pharmacology Q&A | Pharmacology

1. A 32-year-old patient with mild intermittent asthma reports using a rescue
inhaler less than twice per week and has no nighttime awakenings.
According to GINA guidelines, which treatment is most appropriate?

A) Daily low-dose inhaled corticosteroid (ICS)

B) As-needed low-dose ICS-formoterol OR as-needed low-dose ICS with SABA

C) Daily medium-dose ICS with LABA

D) Daily low-dose ICS-formoterol



Correct Answer: As-needed low-dose ICS-formoterol OR as-needed low-dose
ICS with SABA



Rationale: For patients with symptoms less than twice per month,
intermittent symptoms can be managed with as-needed controller
medication to reduce inflammation and prevent exacerbations. Formoterol is
a fast-acting LABA suitable for reliever use when combined with ICS. Daily
ICS is reserved for more frequent symptoms.



2. A patient with asthma reports daytime symptoms more than twice per
week but less than daily, with occasional nighttime awakenings. What is the
recommended step therapy according to GINA guidelines?

A) As-needed SABA only

B) Daily low-dose ICS and as-needed SABA OR as-needed low-dose ICS-
formoterol

C) Daily medium-dose ICS with LABA

D) Daily high-dose ICS with LABA



Correct Answer: Daily low-dose ICS and as-needed SABA OR as-needed low-
dose ICS-formoterol

,Rationale: More frequent symptoms (more than twice per month) require
daily anti-inflammatory control with ICS; SABAs provide symptom relief. As-
needed ICS-formoterol simplifies regimen and provides both reliever and
anti-inflammatory effects.



3. A 45-year-old patient with asthma reports symptoms on most days of the
week. Which treatment step is most appropriate?

A) Daily low-dose ICS and as-needed SABA

B) Daily low-dose ICS-formoterol and as-needed SABA OR daily medium-dose
ICS and SABA

C) Daily high-dose ICS with LABA

D) As-needed ICS-formoterol only



Correct Answer: Daily low-dose ICS-formoterol and as-needed SABA OR daily
medium-dose ICS and SABA



Rationale: Frequent symptoms indicate need for increased ICS dose or
combination with formoterol for better control; medium-dose ICS better
controls persistent inflammation. Daily low-dose ICS alone is insufficient for
symptoms on most days.



4. A patient with severe asthma has daily symptoms despite medium-dose
ICS-formoterol. What is the next step in therapy?

A) Add a leukotriene receptor antagonist

B) Daily medium-dose ICS-formoterol with reliever therapy OR daily high-
dose ICS with reliever therapy

C) Switch to oral corticosteroids

D) Add theophylline



Correct Answer: Daily medium-dose ICS-formoterol with reliever therapy OR
daily high-dose ICS with reliever therapy

,Rationale: Severe asthma requires higher anti-inflammatory doses combined
with fast-acting bronchodilators to manage persistent symptoms and reduce
exacerbations. Adding a leukotriene receptor antagonist or theophylline may
be considered as adjunctive therapy, but the primary step is increasing ICS
dose.



5. Which of the following symptoms indicates uncontrolled asthma according
to GINA guidelines? (Select all that apply)

A) Daytime asthma more than 2 times a week

B) Nighttime awakenings

C) Reliever therapy more than 2 times a week

D) Activity intolerance



Correct Answer: Daytime asthma more than 2 times a week, Nighttime
awakenings, Reliever therapy more than 2 times a week, Activity intolerance



Rationale: These symptoms indicate poor asthma control and higher risk of
exacerbations, thus requiring treatment step-up or reassessment. The
presence of at least three of these symptoms suggests uncontrolled asthma
requiring treatment escalation.



6. Which beta-blocker is contraindicated in patients with asthma due to non-
selective beta-blockade causing bronchospasm?

A) Metoprolol

B) Atenolol

C) Propranolol

D) Bisoprolol



Correct Answer: Propranolol

, Rationale: Non-selective beta-blockers (propranolol, nadolol, timolol, sotalol)
block β2 receptors in the lungs, causing bronchospasm in asthma patients.
Cardioselective beta-blockers (metoprolol, atenolol, bisoprolol) have lower
risk of bronchospasm and may be used with caution in asthma patients when
necessary.



7. A patient with COPD is classified as GOLD Group B. Which initial
pharmacotherapy is recommended?

A) LAMA alone OR LABA + LAMA

B) LABA alone

C) ICS + LABA

D) Theophylline



Correct Answer: LAMA alone OR LABA + LAMA



Rationale: GOLD Group B patients have more symptoms but low
exacerbation risk. LAMA or LABA + LAMA is recommended for initial therapy.
ICS-containing regimens are reserved for patients with higher exacerbation
risk (Groups D and E).



8. A patient with COPD and frequent exacerbations (≥2 per year) is classified
as GOLD Group E. Which treatment is most appropriate?

A) LAMA alone

B) LABA alone

C) LABA + LAMA OR LABA + ICS

D) Theophylline only



Correct Answer: LABA + LAMA OR LABA + ICS

Información del documento

Subido en
11 de agosto de 2026
Número de páginas
49
Escrito en
2026/2027
Tipo
Examen
Contiene
Preguntas y respuestas
$15.99

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Seller avatar
Los indicadores de reputación están sujetos a la cantidad de artículos vendidos por una tarifa y las reseñas que ha recibido por esos documentos. Hay tres niveles: Bronce, Plata y Oro. Cuanto mayor reputación, más podrás confiar en la calidad del trabajo del vendedor.
ExamStudy
3.0
(1)
Vendido
11
Seguidores
0
Artículos
1177
Última venta
3 días hace




Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes